PD-1 Blockade in GBM: Uncovering Response Clues.
Although glioblastoma multiforme is generally considered unresponsive to immunotherapy, findings from three recent studies provide molecular clues that may help clinicians figure out which patients are more likely to benefit from this treatment. The results also suggest that the timing of PD-1 blockade may be critical in promoting therapeutic efficacy.